Lamotrigine in pregnancy-therapeutic drug monitoring in maternal blood, amniotic fluid, and cord blood

International Clinical Psychopharmacology

Volumn 30, Issue 5, 2015, Pages 249-254

  Paulzen, Michael ^a   Lammertz, Sarah E ^a   Veselinovic, Tanja ^a   Goecke, Tamme W ^a   Hiemke, Christoph ^b   Gründer, Gerhard ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

amniotic fluid; cord blood; epilepsy; lamotrigine; mood stabilizer; pharmacokinetics; placental transfer; pregnancy; therapeutic drug monitoring

Indexed keywords

CLOBAZAM; ETIRACETAM; LAMOTRIGINE; ANTICONVULSIVE AGENT; TRIAZINE DERIVATIVE;

ADULT; AMNION FLUID; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIGEORGE SYNDROME; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MONITORING; FEMALE; FETUS CIRCULATION; HEART VENTRICLE SEPTUM DEFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ICD-10; LOW BIRTH WEIGHT; MATERNAL BLOOD; MATERNAL SERUM; OBSERVATIONAL STUDY; PLACENTAL TRANSFER; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY DISTRESS SYNDROME; UMBILICAL CORD BLOOD; YOUNG ADULT; BLOOD; FETUS BLOOD; METABOLISM; NEWBORN; PREGNANCY;

ADULT; AMNIOTIC FLUID; ANTICONVULSANTS; DRUG MONITORING; FEMALE; FETAL BLOOD; HUMANS; INFANT, NEWBORN; PREGNANCY; TRIAZINES; YOUNG ADULT;

EID: 84939557109     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000088     Document Type: Article

References (29)

1. Aston SA. (2014). James G. Wilsons six principles of teratology. Embryo project encyclopedia. Available at: https://embryo.asu.edu/pages/james-g-wilsonssix-principles-teratology. [Accessed 10 June 2014
2. Bromley R, Weston J, Adab N, Greenhalgh J, Sanniti A, McKay AJ, et al. (2014). Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev 10: CD010236
3. Chen H, Yang K, Choi S, Fischer JH, Jeong H. (2009). Up-regulation of UDPglucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. Drug Metab Dispos 37: 1841-1847
4. Clark CT, Klein AM, Perel JM, Helsel J, Wisner KL. (2013). Lamotrigine dosing for pregnant patients with bipolar disorder. Am J Psychiatry 170: 1240-1247
5. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. (1987). Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 42: 535-541
6. Cunnington MC, Weil JG, Messenheimer JA, Ferber S, Yerby M, Tennis P. (2011). Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 76: 1817-1823
7. Eshkoli T, Sheiner E, Ben-Zvi Z, Feinstein V, Holcberg G. (2011). Drug transport across the placenta. Curr Pharm Biotechnol 12: 707-714
8. Ganapathy V, Prasad PD, Ganapathy ME, Leibach FH. (2000). Placental transporters relevant to drug distribution across the maternal-fetal interface. J Pharmacol Exp Ther 294: 413-420
9. Giaginis C, Theocharis S, Tsantili-Kakoulidou A. (2012). Current toxicological aspects on drug and chemical transport and metabolism across the human placental barrier. Expert Opin Drug Metab Toxicol 8: 1263-1275
10. Glaxosmithkline. (2014). Product Monograph Lamictal (Lamotrigin) Available at: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing-Information/Lamictal/pdf/LAMICTAL-PI-MG.PDF. [Accessed 3 June 2015
11. Green MD, Bishop WP, Tephly TR. (1995). Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides. Drug Metab Dispos 23: 299-302
12. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. (2010). A metaanalysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry 67: 1012-1024
13. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. (2011). AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44: 195-235
14. Hostetter A, Ritchie JC, Stowe ZN. (2000). Amniotic fluid and umbilical cord blood concentrations of antidepressants in three women. Biol Psychiatry 48: 1032-1034
15. Hutson JR, Garcia-Bournissen F, Davis A, Koren G. (2011). The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs. Clin Pharmacol Ther 90: 67-76
16. Kallen B, Borg N, Reis M. (2013). The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel) 6: 1221-1286
17. Klys M, Rojek S, Rzepecka-Wozniak E. (2007). Neonatal death following clozapine self-poisoning in late pregnancy: an unusual case report. Forensic Sci Int 171: e5-e10
18. Loughhead AM, Fisher AD, Newport DJ, Ritchie JC, Owens MJ, deVane CL, Stowe ZN. (2006). Antidepressants in amniotic fluid: another route of fetal exposure. Am J Psychiatry 163: 145-147
19. Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J, et al. (2012). Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years. Neurology 78: 1207-1214
20. Newport DJ, Calamaras MR, deVane CL, Donovan J, Beach AJ, Winn S, et al. (2007). Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 164: 1214-1220
21. Nulman I, Koren G, Rovet J, Barrera M, Pulver A, Streiner D, Feldman B. (2012). Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry 169: 1165-1174
22. Reid JG, Gitlin MJ, Altshuler LL. (2013). Lamotrigine in psychiatric disorders. J Clin Psychiatry 74: 675-6784
23. Reimers A, Ostby L, Stuen I, Sundby E. (2011). Expression of UDPglucuronosyltransferase 1A4 in human placenta at term. Eur J Drug Metab Pharmacokinet 35: 79-82
24. Schaefer C. (2011). Drug safety in pregnancy: utopia or achievable prospect?. Risk information, risk research and advocacy in Teratology Information Services. Congenit Anom (Kyoto) 51: 6-11
25. Thomas SH, Yates LM. (2012). Prescribing without evidence -pregnancy. Br J Clin Pharmacol 74: 691-697
26. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. (2011). Dosedependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 10: 609-617
27. Uguz F, Gezginc K, Yazici F. (2011). Are major depression and generalized anxiety disorder associated with intrauterine growth restriction in pregnant women?. A case-control study. Gen Hosp Psychiatry 33: 640.e7-9
28. Vajda FJ, OBrien TJ, Graham J, Lander CM, Eadie MJ. (2015). The outcomes of pregnancy in women with untreated epilepsy. Seizure 24: 77-81
29. Wilson JG. (1973). Environment and birth defects. NY, USA: Academic Press